CrossrefInfokarte
First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension
Pulmonary Pharmacology & Therapeutics · 2026-12 · 95 · 102453
DOI: 10.1016/j.pupt.2026.102453 ↗Abstract
Kein Abstract verfügbar.
EUVIMED